Ansel Shao Pin Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ansel Shao Pin Tang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas Wen Sheng Chew
Department of Cardiology, National University Heart Centre, National University Health System
5 shared publications - Cheng Han Ng
Division of Gastroenterology, Department of Medicine Kurume University School of Medicine Kurume Japan
4 shared publications - Daniel Q. Huang
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
4 shared publications - Darren Jun Hao Tan
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
4 shared publications - Kai En Chan
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
4 shared publications - Mark Dhinesh Muthiah
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; National University Centre for Digestive Health, National University Hospital, Singapore, Singapore; National University Centre for Organ Transplantation, National University Hospital, Singapore, Singapore
4 shared publications
Latest Publications
- Open Access
- 30 July 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31  (3) , 296-303
Diagnostic Criteria and Symptom Profiles in Adult Idiopathic Gastroparesis: A Systematic Review
Adult idiopathic gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, and postprandial fullness. Diagnostic criteria vary across studies, leading to inconsistencies in diagnosis and management. This systematic review explores the diagnostic criteria and categorization of definite, probable, and possible idiopathic gastroparesis in the literature. Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we searched Medline, EMBASE, and Cochrane Library databases for relevant articles published in English up to January 2024. Observational studies (cross-sectional, case-control, and cohort designs) that provided diagnostic criteria for idiopathic gastroparesis were included. Data were extracted on demographics, co-existing conditions, symptoms, and diagnostic approaches. Quality was assessed using Joanna Briggs Institute checklists. Of 2235 initial results, 11 studies met our inclusion criteria. Most studies were of high quality, exclusively from Western research centers, and had a preponderance of female patients (61.7% to 85.9%) with mean ages ranging from 40.0 years to 58.9 years. Diagnostic variability was noted. A definite diagnosis was most often based on clinical symptoms and positive gastric emptying scintigraphy, while probable gastroparesis was identified by suggestive symptoms with normal upper endoscopy findings. Nausea and upper abdominal pain were frequently reported symptoms. Significant overlaps were observed between idiopathic gastroparesis and functional dyspepsia. The findings highlight the inherent diagnostic challenges and underscores the need for confirming delayed gastric emptying to clinch an accurate diagnosis of gastroparesis. Future research should focus on developing consistent diagnostic criteria across diverse populations to improve the diagnosis and management of idiopathic gastroparesis.
- 30 July 2025
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 31  (3) , 296-303
Open AccessDiagnostic Criteria and Symptom Profiles in Adult Idiopathic Gastroparesis: A Systematic Review
Adult idiopathic gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, and postprandial fullness. Diagnostic criteria vary across studies, leading to inconsistencies in diagnosis and management. This systematic review explores the diagnostic criteria and categorization of definite, probable, and possible idiopathic gastroparesis in the literature. Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we searched Medline, EMBASE, and Cochrane Library databases for relevant articles published in English up to January 2024. Observational studies (cross-sectional, case-control, and cohort designs) that provided diagnostic criteria for idiopathic gastroparesis were included. Data were extracted on demographics, co-existing conditions, symptoms, and diagnostic approaches. Quality was assessed using Joanna Briggs Institute checklists. Of 2235 initial results, 11 studies met our inclusion criteria. Most studies were of high quality, exclusively from Western research centers, and had a preponderance of female patients (61.7% to 85.9%) with mean ages ranging from 40.0 years to 58.9 years. Diagnostic variability was noted. A definite diagnosis was most often based on clinical symptoms and positive gastric emptying scintigraphy, while probable gastroparesis was identified by suggestive symptoms with normal upper endoscopy findings. Nausea and upper abdominal pain were frequently reported symptoms. Significant overlaps were observed between idiopathic gastroparesis and functional dyspepsia. The findings highlight the inherent diagnostic challenges and underscores the need for confirming delayed gastric emptying to clinch an accurate diagnosis of gastroparesis. Future research should focus on developing consistent diagnostic criteria across diverse populations to improve the diagnosis and management of idiopathic gastroparesis.
- Open Access
- 1 July 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54  (7)
Evaluating the role of clinical decision support systems in medication safety for older people: a systematic review
Background: Older people are particularly vulnerable to medication errors and adverse drug events (ADEs) due to polypharmacy and age-related physiological changes. Clinical decision support systems (CDSS) presents itself as a potential solution for clinicians, but their effectiveness in care for older people remains uncertain. Objectives: To evaluate the impact of CDSS on reducing potentially inappropriate medications (PIMs) and improving medication safety amongst older people. Design and Setting: This was a systematic review of randomized controlled trials (RCTs) evaluating CDSS interventions in older populations (aged 65 or older). Methods: A comprehensive search was conducted in OVID Medline, Embase, and Cochrane Library from inception to April 2025. Eligible studies were RCTs assessing CDSS in reducing PIM use and ADEs amongst older people. Data on medication safety outcomes (PIM, deprescription and ADEs) were extracted. The findings were narratively synthesized, and the certainty of evidence was evaluated using the GRADE framework. The Cochrane Risk-of-Bias 2 tool was also applied. Results: A total of 16 RCTs (comprising 135,108 participants) were included. CDSS significantly reduced PIM initiation by up to 18% (moderate certainty) and improved deprescription rates, with intervention groups achieving 55.4% PIM discontinuation. However, CDSS had inconsistent effects on ADEs (low certainty). Conclusions: CDSS improved prescribing practices by reducing inappropriate medication use in older people. However, its impact on ADEs was less evident. Implementation challenges such as clinician adherence, alert fatigue and system usability must be addressed to optimize CDSS effectiveness in care for older people. Further research is needed for long-term evaluation and refinement of CDSS.
- 1 July 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54  (7)
Open AccessEvaluating the role of clinical decision support systems in medication safety for older people: a systematic review
Background: Older people are particularly vulnerable to medication errors and adverse drug events (ADEs) due to polypharmacy and age-related physiological changes. Clinical decision support systems (CDSS) presents itself as a potential solution for clinicians, but their effectiveness in care for older people remains uncertain. Objectives: To evaluate the impact of CDSS on reducing potentially inappropriate medications (PIMs) and improving medication safety amongst older people. Design and Setting: This was a systematic review of randomized controlled trials (RCTs) evaluating CDSS interventions in older populations (aged 65 or older). Methods: A comprehensive search was conducted in OVID Medline, Embase, and Cochrane Library from inception to April 2025. Eligible studies were RCTs assessing CDSS in reducing PIM use and ADEs amongst older people. Data on medication safety outcomes (PIM, deprescription and ADEs) were extracted. The findings were narratively synthesized, and the certainty of evidence was evaluated using the GRADE framework. The Cochrane Risk-of-Bias 2 tool was also applied. Results: A total of 16 RCTs (comprising 135,108 participants) were included. CDSS significantly reduced PIM initiation by up to 18% (moderate certainty) and improved deprescription rates, with intervention groups achieving 55.4% PIM discontinuation. However, CDSS had inconsistent effects on ADEs (low certainty). Conclusions: CDSS improved prescribing practices by reducing inappropriate medication use in older people. However, its impact on ADEs was less evident. Implementation challenges such as clinician adherence, alert fatigue and system usability must be addressed to optimize CDSS effectiveness in care for older people. Further research is needed for long-term evaluation and refinement of CDSS.
- Open Access
- 24 May 2024
- Published by MDPI AG in Healthcare
- Vol. 12  (11) , 1079
A Systematic Review of the Reliability and Validity of the Patient Activation Measure Tool
Patient activation, broadly defined as the ability of individuals to manage their health and navigate the healthcare system effectively, is crucial for achieving positive health outcomes. The Patient Activation Measure (PAM), a popularly used tool, was developed to assess this vital component of health care. This review is the first to systematically examine the validity of the PAM, as well as study its reliability, factor structure, and validity across various populations. Following the PRISMA and COSMIN guidelines, a search was conducted in MEDLINE, EMBASE, and Cochrane Library, from inception to 1 October 2023, using combinations of keywords related to patient activation and the PAM. The inclusion criteria were original quantitative or mixed methods studies focusing on PAM-13 or its translated versions and containing data on psychometric properties. Out of 3007 abstracts retrieved, 39 studies were included in the final review. The PAM has been extensively studied across diverse populations and geographical regions, including the United States, Europe, Asia, and Australia. Most studies looked at populations with chronic conditions. Only two studies applied the PAM to community-dwelling individuals and found support for its use. Studies predominantly showed a high internal consistency (Cronbach’s alpha > 0.80) for the PAM. Most studies supported a unidimensional construct of patient activation, although cultural differences influenced the factor structure in some cases. Construct validity was established through correlations with health behaviors and outcomes. Despite its strengths, there is a need for further research, particularly in exploring content validity and differential item functioning. Expanding the PAM’s application to more diverse demographic groups and community-dwelling individuals could enhance our understanding of patient activation and its impact on health outcomes.
- 24 May 2024
- Published by MDPI AG in Healthcare
- Vol. 12  (11) , 1079
Open AccessA Systematic Review of the Reliability and Validity of the Patient Activation Measure Tool
Patient activation, broadly defined as the ability of individuals to manage their health and navigate the healthcare system effectively, is crucial for achieving positive health outcomes. The Patient Activation Measure (PAM), a popularly used tool, was developed to assess this vital component of health care. This review is the first to systematically examine the validity of the PAM, as well as study its reliability, factor structure, and validity across various populations. Following the PRISMA and COSMIN guidelines, a search was conducted in MEDLINE, EMBASE, and Cochrane Library, from inception to 1 October 2023, using combinations of keywords related to patient activation and the PAM. The inclusion criteria were original quantitative or mixed methods studies focusing on PAM-13 or its translated versions and containing data on psychometric properties. Out of 3007 abstracts retrieved, 39 studies were included in the final review. The PAM has been extensively studied across diverse populations and geographical regions, including the United States, Europe, Asia, and Australia. Most studies looked at populations with chronic conditions. Only two studies applied the PAM to community-dwelling individuals and found support for its use. Studies predominantly showed a high internal consistency (Cronbach’s alpha > 0.80) for the PAM. Most studies supported a unidimensional construct of patient activation, although cultural differences influenced the factor structure in some cases. Construct validity was established through correlations with health behaviors and outcomes. Despite its strengths, there is a need for further research, particularly in exploring content validity and differential item functioning. Expanding the PAM’s application to more diverse demographic groups and community-dwelling individuals could enhance our understanding of patient activation and its impact on health outcomes.
- Open Access
- 20 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9  (10) , e1537
Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients
Background.: Immunocompromised individuals have been excluded from landmark studies of messenger RNA vaccinations for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). In such patients, the response to vaccination may be blunted and may wane more quickly compared with immunocompetent patients. We studied the factors associated with decreased antibody response to SARS-CoV-2 vaccination and risk factors for subsequent breakthrough infections in liver transplant (LT) patients undergoing coronavirus disease 2019 vaccination with at least 2 doses of messenger RNA vaccine from April 28, 2021, to April 28, 2022. Methods.: All LT recipients received at least 2 doses of the BNT162b2 (Pfizer BioNTech) vaccine 21 d apart. We measured the antibody response against the SARS-CoV-2 spike protein using the Roche Elecsys immunoassay to the receptor-binding domain of the SARS-CoV-2 spike protein, and the presence of neutralizing antibodies was measured by the surrogate virus neutralization test (cPass) before first and second doses of vaccination and also between 2 and 3 mo after the second dose of vaccination. Results.: Ninety-three LT recipients who received 2 doses of BNT162b2 were included in the analysis. The mean time from LT was 110 ± 154 mo. After 2-dose vaccination, 38.7% of LT recipients (36/93) were vaccine nonresponders on the cPass assay compared with 20.4% (19/93) on the Roche S assay. On multivariable analysis, increased age and increased tacrolimus trough were found to be associated with poor neutralizing antibody response (P = 0.038 and 0.022, respectively). The use of antimetabolite therapy in conjunction with tacrolimus approached statistical significance (odds ratio 0.21; 95% confidence interval, 0.180-3.72; P = 0.062). Breakthrough infection occurred in 18 of 88 LT recipients (20.4%). Female gender was independently associated with breakthrough infections (P < 0.001). Conclusions.: Among LT recipients, older age and higher tacrolimus trough levels were associated with poorer immune response to 2-dose SARS-CoV-2 vaccination. Further studies are needed to assess variables associated with breakthrough infections and, hence, who should be prioritized for booster vaccination.
- 20 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9  (10) , e1537
Open AccessClinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients
Background.: Immunocompromised individuals have been excluded from landmark studies of messenger RNA vaccinations for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). In such patients, the response to vaccination may be blunted and may wane more quickly compared with immunocompetent patients. We studied the factors associated with decreased antibody response to SARS-CoV-2 vaccination and risk factors for subsequent breakthrough infections in liver transplant (LT) patients undergoing coronavirus disease 2019 vaccination with at least 2 doses of messenger RNA vaccine from April 28, 2021, to April 28, 2022. Methods.: All LT recipients received at least 2 doses of the BNT162b2 (Pfizer BioNTech) vaccine 21 d apart. We measured the antibody response against the SARS-CoV-2 spike protein using the Roche Elecsys immunoassay to the receptor-binding domain of the SARS-CoV-2 spike protein, and the presence of neutralizing antibodies was measured by the surrogate virus neutralization test (cPass) before first and second doses of vaccination and also between 2 and 3 mo after the second dose of vaccination. Results.: Ninety-three LT recipients who received 2 doses of BNT162b2 were included in the analysis. The mean time from LT was 110 ± 154 mo. After 2-dose vaccination, 38.7% of LT recipients (36/93) were vaccine nonresponders on the cPass assay compared with 20.4% (19/93) on the Roche S assay. On multivariable analysis, increased age and increased tacrolimus trough were found to be associated with poor neutralizing antibody response (P = 0.038 and 0.022, respectively). The use of antimetabolite therapy in conjunction with tacrolimus approached statistical significance (odds ratio 0.21; 95% confidence interval, 0.180-3.72; P = 0.062). Breakthrough infection occurred in 18 of 88 LT recipients (20.4%). Female gender was independently associated with breakthrough infections (P < 0.001). Conclusions.: Among LT recipients, older age and higher tacrolimus trough levels were associated with poorer immune response to 2-dose SARS-CoV-2 vaccination. Further studies are needed to assess variables associated with breakthrough infections and, hence, who should be prioritized for booster vaccination.
- Open Access
- 21 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11  (20) , 6205
DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide yet predicting non-obese NAFLD is challenging. Thus, this study investigates the potential of regional fat percentages obtained by dual-energy X-ray absorptiometry (DXA) in accurately assessing NAFLD risk. Using the United States National Health and Nutrition Examination Survey (NHANES) 2011–2018, multivariate logistic regression and marginal analysis were conducted according to quartiles of regional fat percentages, stratified by gender. A total of 23,752 individuals were analysed. Males generally showed a larger increase in marginal probabilities of NAFLD development than females, except in head fat, which had the highest predictive probabilities of non-obese NAFLD in females (13.81%, 95%CI: 10.82–16.79) but the lowest in males (21.89%, 95%CI: 20.12–23.60). Increased percent of trunk fat was the strongest predictor of both non-obese (OR: 46.61, 95%CI: 33.55–64.76, p < 0.001) and obese NAFLD (OR: 2.93, 95%CI: 2.07–4.15, p < 0.001), whereas raised percent gynoid and leg fat were the weakest predictors. Ectopic fat deposits are increased in patients with non-obese NAFLD, with greater increases in truncal fat over gynoid fat. As increased fat deposits in all body regions can increase odds of NAFLD, therapeutic intervention to decrease ectopic fat, particularly truncal fat, may decrease NAFLD risk.
- 21 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11  (20) , 6205
Open AccessDEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide yet predicting non-obese NAFLD is challenging. Thus, this study investigates the potential of regional fat percentages obtained by dual-energy X-ray absorptiometry (DXA) in accurately assessing NAFLD risk. Using the United States National Health and Nutrition Examination Survey (NHANES) 2011–2018, multivariate logistic regression and marginal analysis were conducted according to quartiles of regional fat percentages, stratified by gender. A total of 23,752 individuals were analysed. Males generally showed a larger increase in marginal probabilities of NAFLD development than females, except in head fat, which had the highest predictive probabilities of non-obese NAFLD in females (13.81%, 95%CI: 10.82–16.79) but the lowest in males (21.89%, 95%CI: 20.12–23.60). Increased percent of trunk fat was the strongest predictor of both non-obese (OR: 46.61, 95%CI: 33.55–64.76, p < 0.001) and obese NAFLD (OR: 2.93, 95%CI: 2.07–4.15, p < 0.001), whereas raised percent gynoid and leg fat were the weakest predictors. Ectopic fat deposits are increased in patients with non-obese NAFLD, with greater increases in truncal fat over gynoid fat. As increased fat deposits in all body regions can increase odds of NAFLD, therapeutic intervention to decrease ectopic fat, particularly truncal fat, may decrease NAFLD risk.
- 9 August 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58  (1) , 76-82
Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography
As the global prevalence of non-alcoholic fatty liver disease (NAFLD) continues to rise, ubiquity of alcohol use has also prompted discussion regarding the potential interactions between the two. T...
- 9 August 2022
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 58  (1) , 76-82
Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography
As the global prevalence of non-alcoholic fatty liver disease (NAFLD) continues to rise, ubiquity of alcohol use has also prompted discussion regarding the potential interactions between the two. T...
- Open Access
- 30 May 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000  (000) , 000
A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
Pharmaceutical therapy for NASH is associated with lipid modulation, but the consensus on drug treatment is limited and lacks comparative analysis of effectiveness. A network meta-analysis was conducted to compare NASH drug classes in lipid modulation.
- 30 May 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000  (000) , 000
Open AccessA Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
Pharmaceutical therapy for NASH is associated with lipid modulation, but the consensus on drug treatment is limited and lacks comparative analysis of effectiveness. A network meta-analysis was conducted to compare NASH drug classes in lipid modulation.